TY - JOUR
T1 - Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes
AU - Paulus, Yannis M.
AU - Jefferys, Joan L.
AU - Hawkins, Barbara S.
AU - Scott, Adrienne W.
N1 - Funding Information:
Funding was provided in part by the Heed Ophthalmic Foundation Fellows Grant (YMP) and the National Eye Institute Michigan Vision Clinician-Scientist Development Program 4K12EY022299-4 (YMP). The authors also received support from an unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness, New York, New York. The authors would like to thank Judith E. Goldstein, O.D., for careful review of the manuscript.
Publisher Copyright:
© 2017, Springer International Publishing Switzerland.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Purpose: To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD). Methods: We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores. Results: CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales. Conclusion: CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
AB - Purpose: To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD). Methods: We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores. Results: CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales. Conclusion: CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
KW - Age-related macular degeneration
KW - Choroidal neovascularization
KW - National Eye Institute Visual Function Questionnaire
KW - Quality of Life
KW - Second eyes
KW - Submacular Surgery Trials
UR - http://www.scopus.com/inward/record.url?scp=85016434897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016434897&partnerID=8YFLogxK
U2 - 10.1007/s11136-017-1547-z
DO - 10.1007/s11136-017-1547-z
M3 - Article
C2 - 28357680
AN - SCOPUS:85016434897
SN - 0962-9343
VL - 26
SP - 2139
EP - 2151
JO - Quality of Life Research
JF - Quality of Life Research
IS - 8
ER -